Glucarpidase

證據等級: L5

預測適應症: 10 個

Glucarpidase: From Methotrexate Toxicity to Diabetic Cataract

One-Sentence Summary

Glucarpidase (DrugBank DB08898) is a recombinant bacterial enzyme (carboxypeptidase G2) used as an emergency antidote to inactivate toxic methotrexate levels. The TxGNN model predicts a possible effect on Diabetic Cataract and nine other cataract/retinopathy-related conditions, but no clinical trials or literature currently support any of these predictions, and the mechanistic rationale provided is explicitly assessed as biologically implausible.

Quick Overview

Item	Content
Original Indication	Methotrexate (MTX) toxicity — emergency detoxification (derived from evidence pack rationale; no formal indication text on file)
Predicted New Indication	Diabetic Cataract
TxGNN Prediction Score	99.85%
Evidence Level	L5 (model prediction only, no supporting studies)
Germany Market Status	✗ Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available (Data Gap). Based on the information present in this evidence pack, glucarpidase's only well-established biological activity is hydrolyzing the terminal glutamate residue of methotrexate, which inactivates the drug and is used clinically for MTX overdose rescue. This is a highly specific, single-substrate enzymatic function with no known involvement in lens metabolism, advanced glycation end-product (AGE) accumulation, oxidative stress, retinal microvascular pathology, or calcium/parathyroid pathways — the mechanisms typically implicated in cataract and diabetic retinopathy.

The evidence pack's own repurposing rationale for every one of the top 10 predicted indications (all cataract subtypes and diabetic retinopathy) states there is no known mechanistic link between glucarpidase and these conditions, and attributes the high TxGNN scores to sparse indirect graph connections (e.g., co-occurrence of "enzyme-class drug" and "metabolic eye disease" nodes) rather than genuine pharmacological plausibility.

Given that the original indication (acute MTX toxicity, a single-dose IV rescue therapy) has no logical or mechanistic relationship to chronic ophthalmic conditions like cataract, this prediction cluster should be treated as a low-confidence graph-topology artifact rather than a credible repurposing hypothesis.

Clinical Trial Evidence

Currently no related clinical trials registered

Literature Evidence

Currently no related literature available

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: All 10 predicted indications (diabetic cataract, diabetic retinopathy, and 8 other cataract subtypes) carry Evidence Level L5 with zero supporting clinical trials or literature, and the evidence pack's own mechanistic analysis explicitly concludes there is no biological plausibility linking glucarpidase's known enzymatic activity to any of these ophthalmic conditions.

To proceed, the following is needed:

Confirmed mechanism of action (MOA) data for glucarpidase (currently Data Gap, DG002)
TFDA/manufacturer package insert warnings and contraindications (currently Data Gap, DG001 — Blocking)
Independent preclinical or mechanistic studies establishing a plausible pathway between carboxypeptidase G2 activity and lens/retinal pathology before any further evaluation is warranted
Re-evaluation should only be triggered if new literature or trial data emerges; no active investment is recommended at this time
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.